Overview

Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions

Status:
Active, not recruiting

Trial end date:
2020-12-20

Target enrollment:

Participant gender:

Summary

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

Phase:

Phase 1

Details

Lead Sponsor:

Pharma Plant

Collaborator:

Novagenix Bioanalytical Drug R&D Center

Treatments:

Favipiravir